One of the greatest points of contention in reviewing these bills has been the exclusivity period that should be granted to the drug companies before the biosimilars can enter the market.
Brand name drug and biotechnology companies argue for longer exclusivity periods, about 12-14 years, asserting that a shorter exclusivity period would endanger incentives for innovation.